On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% Friday, halting the momentum the stock generated just a day earlier after ...

The restructuring enacted by Sarepta Therapeutics is expected to save up to $400 million in annual costs. Read why I'm ...

Sarepta stock crashed Friday on reports the FDA will ask the biotech company to stop shipments of its approved gene therapy, ...

Drugmaker Sarepta Therapeutics said late Friday it will not comply with a request from the Food and Drug Administration to ...

Learn about the executive team and board of directors at Sarepta Therapeutics Inc (1SRPT:XMIL) and review their bios and compensation over the latest fiscal years.

Following an advance to all-time highs, S&P 500 edged lower. Short-dated Treasuries led gains after Waller hinted he would ...

Stocks rebounded on Wednesday after President Donald Trump denied reports that he was close to ousting Powell as chairman of ...

Stocks wavered amid earnings. President Donald Trump signed the stablecoins bill in a win for the crypto industry.